SEC INSIDER TRANSACTIONS

TEXAS INSTRUMENTS INC (TXN) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

TXN · TEXAS INSTRUMENTS INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 14 filings · fetched 2026-11-13T20:20:13Z

Recent reported activity

0purchase rows on this page

6sale rows on this page

39matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-05-14Filed 2026-05-15	BAHAI AHMADOfficer · Sr. Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.85 to $309.53. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The option became exercisable in four equal annual installments beginning on January 25, 2019. References: F2	M Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	5,000D	0	Direct	Form 4 ↗0000097476-26-000141
2026-05-14Filed 2026-05-15	BAHAI AHMADOfficer · Sr. Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.85 to $309.53. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The option became exercisable in four equal annual installments beginning on January 25, 2019. References: F1	S Sale (market/private)Common Stock · Non-derivative	5,000D	309.1272	Direct	Form 4 ↗0000097476-26-000141
2026-05-14Filed 2026-05-15	BAHAI AHMADOfficer · Sr. Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.85 to $309.53. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The option became exercisable in four equal annual installments beginning on January 25, 2019. References:	M Exercise / conversionCommon Stock · Non-derivative	5,000A	110.15	Direct	Form 4 ↗0000097476-26-000141
2026-05-14Filed 2026-05-15	Lizardi Rafael ROfficer · Sr. Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $307.29 to $308.29. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.30 to $309.16. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $309.32 to $309.80. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F4 The option became exercisable in four equal annual installments beginning on January 27, 2023. References: F4	M Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	47,734D	0	Direct	Form 4 ↗0000097476-26-000140
2026-05-14Filed 2026-05-15	Lizardi Rafael ROfficer · Sr. Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $307.29 to $308.29. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.30 to $309.16. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $309.32 to $309.80. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F4 The option became exercisable in four equal annual installments beginning on January 27, 2023. References: F3	S Sale (market/private)Common Stock · Non-derivative	1,459D	309.4487	Direct	Form 4 ↗0000097476-26-000140
2026-05-14Filed 2026-05-15	Lizardi Rafael ROfficer · Sr. Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $307.29 to $308.29. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.30 to $309.16. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $309.32 to $309.80. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F4 The option became exercisable in four equal annual installments beginning on January 27, 2023. References: F2	S Sale (market/private)Common Stock · Non-derivative	14,156D	308.5448	Direct	Form 4 ↗0000097476-26-000140
2026-05-14Filed 2026-05-15	Lizardi Rafael ROfficer · Sr. Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $307.29 to $308.29. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.30 to $309.16. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $309.32 to $309.80. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F4 The option became exercisable in four equal annual installments beginning on January 27, 2023. References: F1	S Sale (market/private)Common Stock · Non-derivative	32,119D	307.8474	Direct	Form 4 ↗0000097476-26-000140
2026-05-14Filed 2026-05-15	Lizardi Rafael ROfficer · Sr. Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $307.29 to $308.29. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $308.30 to $309.16. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $309.32 to $309.80. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F4 The option became exercisable in four equal annual installments beginning on January 27, 2023. References:	M Exercise / conversionCommon Stock · Non-derivative	47,734A	174.81	Direct	Form 4 ↗0000097476-26-000140
2026-05-13Filed 2026-05-14	COX CARRIE SMITHDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The option became exercisable in four equal annual installments beginning on January 25, 2019. F4 The option became exercisable in four equal annual installments beginning on January 25, 2020. References: F4	M Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	4,532D	0	Direct	Form 4 ↗0000097476-26-000137
2026-05-13Filed 2026-05-14	COX CARRIE SMITHDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The option became exercisable in four equal annual installments beginning on January 25, 2019. F4 The option became exercisable in four equal annual installments beginning on January 25, 2020. References: F3	M Exercise / conversionNQ Stock Option (Right to Buy) · Derivative	4,306D	0	Direct	Form 4 ↗0000097476-26-000137
2026-05-13Filed 2026-05-14	COX CARRIE SMITHDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The option became exercisable in four equal annual installments beginning on January 25, 2019. F4 The option became exercisable in four equal annual installments beginning on January 25, 2020. References: F2	S Sale (market/private)Common Stock · Non-derivative	445D	307.0433	Direct	Form 4 ↗0000097476-26-000137
2026-05-13Filed 2026-05-14	COX CARRIE SMITHDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The option became exercisable in four equal annual installments beginning on January 25, 2019. F4 The option became exercisable in four equal annual installments beginning on January 25, 2020. References: F1	S Sale (market/private)Common Stock · Non-derivative	8,393D	306.3737	Direct	Form 4 ↗0000097476-26-000137
2026-05-13Filed 2026-05-14	COX CARRIE SMITHDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The option became exercisable in four equal annual installments beginning on January 25, 2019. F4 The option became exercisable in four equal annual installments beginning on January 25, 2020. References:	M Exercise / conversionCommon Stock · Non-derivative	4,532A	104.41	Direct	Form 4 ↗0000097476-26-000137
2026-05-13Filed 2026-05-14	COX CARRIE SMITHDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $305.91 to $306.89. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F2 The price in Table 1 is a weighted average sale price. The sales were at prices ranging from $306.94 to $307.24. The Issuer undertakes to provide upon request a detailed breakout of the sale prices and the number of shares sold at each price. F3 The option became exercisable in four equal annual installments beginning on January 25, 2019. F4 The option became exercisable in four equal annual installments beginning on January 25, 2020. References:	M Exercise / conversionCommon Stock · Non-derivative	4,306A	110.15	Direct	Form 4 ↗0000097476-26-000137

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.